ArriVent BioPharma (NASDAQ:AVBP) Given New $39.00 Price Target at HC Wainwright

ArriVent BioPharma (NASDAQ:AVBP) had its price objective increased by HC Wainwright from $36.00 to $39.00 in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

ArriVent BioPharma Stock Up 5.2 %

Shares of NASDAQ:AVBP opened at $26.63 on Wednesday. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $36.37. The company has a 50-day moving average price of $27.00 and a 200 day moving average price of $25.96.

Hedge Funds Weigh In On ArriVent BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Novo Holdings A S lifted its position in ArriVent BioPharma by 39.3% in the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $27,825,000 after buying an additional 422,860 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of ArriVent BioPharma by 154.2% in the 3rd quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock worth $14,036,000 after acquiring an additional 362,221 shares during the last quarter. State Street Corp boosted its stake in shares of ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company’s stock worth $11,205,000 after purchasing an additional 323,186 shares during the period. FMR LLC grew its holdings in ArriVent BioPharma by 8.7% during the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company’s stock valued at $49,813,000 after purchasing an additional 169,514 shares during the last quarter. Finally, Suvretta Capital Management LLC raised its position in ArriVent BioPharma by 7.7% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock worth $43,361,000 after purchasing an additional 132,459 shares during the period. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.